Investor FAQ

Show all

Strongbridge Biopharma is an Irish public limited company.
The U.S. operations are based in Trevose, Pennsylvania, USA.
Strongbridge Biopharma was established in 1996.
Strongbridge Biopharma priced its initial public offering on NASDAQ Global Market on October 16, 2015 and trades under the ticker symbol SBBP.
Strongbridge Biopharma’s CUSIP number is G85347 105.
Communication regarding transfer requirements, lost certificates, changes of address, etc., should be directed to: Computershare

Written Inquiries:

PO Box 43001
Providence RI 02940-30001

Or by overnight delivery:
250 Royall St.
Canton, MA 02021

Email Inquiries:

Telephone Inquiries:
Toll-Free: 866-490-6058 (US, Canada, Puerto Rico)
781-575-2784 (non-US)

Online Inquiries:
Strongbridge Biopharma’s fiscal year end is December 31.
You may sign up to receive Strongbridge Biopharma’s press releases and SEC filings at the following link: Email Alerts.
Strongbridge Biopharma’s U.S. Securities and Exchange Commission filings can be viewed on the SEC page.
For investor relations inquiries, you may submit inquiries via, or by contacting Marcy Nanus at The Trout Group, LLC. at +1-646-378-2927 or

For corporate or media relations inquiries, you may submit inquiries via, or by contacting Lindsay Rocco at Elixir Health Public Relations at +1-862-596-1304 or

© 2018 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
Macrilen is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.
MLR-0010 V14 08/2018

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200

Privacy Statement
Compliance Program